Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive impairment associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes.
Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management.
Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease.
Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.
Actinogen Medical
Alzheimer's disease
Developing Xanamem
"Given the growing number of people with Alzheimer's and the critical importance of finding effective new drugs to treat this disease, our hope is that the development of Xanamem will make a real difference to Alzheimer's patients, and their carers and families worldwide."
DR BILL KETELBEY, CEO & MANAGING DIRECTOR
| 20.02.2020 | Appendix 4D & Half-Year Financial Statements |
| 17.02.2020 | Additional R&D Tax Incentive rebate received |
| 31.01.2020 | Appendix 3Y-Dr Bill Ketelbey |
| 31.01.2020 | ACW – ASIC Form 484 |
| 31.01.2020 | Final share buy-back notice – Appendix 3F |
| 28.01.2020 | December 2019 Quarterly Update |
| 08.01.2020 | Actinogen at SACHS Forum and JP Morgan week |
| 18.12.2019 | Review of 2019 and outlook |
| 13.12.2019 | Share Cancellation – Employee Share Plan |
| 27.11.2019 | Managing Director share loan repayment |
| 25.11.2019 | Results of Annual General Meeting |
| 25.11.2019 | ACW – Managing Director’s AGM Presentation |
| 25.11.2019 | ACW 2019 AGM Chairman’s Address |
| 20.11.2019 | ACW – Response to ASX Price Query |
| 24.10.2019 | R&D Tax Incentive rebate received of $4.58 million |
| 24.10.2019 | September 2019 Quarterly Update |
| 22.10.2019 | Annual Report to shareholders year ended 30 June 2019 |
| 22.10.2019 | ACW – Notice of Annual General Meeting/Proxy Form |
| 01.10.2019 | Cognitive improvement demonstrated with Xanamem |
| 30.09.2019 | Actinogen Medical Conference Call |
| 27.09.2019 | Notification of 2019 Annual General Meeting Date |
| 27.09.2019 | Trading Halt |
| 16.08.2019 | Appendix 4G |
| 16.08.2019 | Appendix 4E & Annual Report |
| 30.07.2019 | June 2019 Quarterly Update |
| 03.07.2019 | Clinical Development and Scientific Conference Update |
| 29.05.2019 | XanaHES Trial to Continue |
| 10.05.2019 | Ceasing to be a substantial holder |
| 08.05.2019 | Ceasing to be a substantial holder from AEF |
| 07.05.2019 | Phase II Alzheimer’s Disease Trial – results |
| 03.05.2019 | Trading Halt |
| 01.05.2019 | Actinogen Updated Investor Presentation |
| 24.04.2019 | March 2019 Quarterly Update |
| 23.04.2019 | Change in substantial holding |
| 15.04.2019 | Lapse of Options |
| 12.04.2019 | Appendix 3Y-Mr Malcolm McComas |
| 12.04.2019 | Appendix 3B |
| 10.04.2019 | New Clinical Development Opportunities for Xanamem |
| 04.04.2019 | Cleansing Notice |
| 04.04.2019 | Appendix 3B |
| 04.04.2019 | Appendix 3X-Malcolm McComas |
| 04.04.2019 | Actinogen Medical appoints new Non-Executive Director |
| 26.03.2019 | DSMB again reaffirms XanADu trial to continue without change |
| 22.03.2019 | Change in substantial holding (Replacement Form 604) |
| 22.03.2019 | Change in substantial holding |
| 21.03.2019 | Actinogen Updated Investor Presentation |
| 19.03.2019 | Appendix 3B |
| 14.03.2019 | Becoming a substantial holder |
| 04.03.2019 | Amended-Notification of Expiry of Listed Options |
| 27.02.2019 | Notification of Expiry of Listed Options |
| 22.02.2019 | ACW-Appendix 4D & Half-Year Financial Statements 31 Dec 2018 |
| 11.02.2019 | First participant dosed in important new Xanamem study: XanaHES |
| 04.02.2019 | Appendix 3B |
| 29.01.2019 | December 2018 Quarterly Update |
| 07.01.2019 | ACW Presents at SACHS Neuroscience Forum during JPM Week |
| 13.12.2018 | Appendix 3Y-Dr George Morstyn |
| 13.12.2018 | Appendix 3Y-Dr Bill Ketelbey |
| 13.12.2018 | Appendix 3Y-Dr Geoff Brooke |
| 13.12.2018 | Appendix 3B |
| 30.11.2018 | Cleansing Notice |
| 30.11.2018 | Appendix 3B-Exercise of Options |
| 28.11.2018 | Appendix 3Z-Dr Jason Loveridge |
| 28.11.2018 | Retirement of Dr Jason Loveridge as a Non-Executive Director |
| 28.11.2018 | Results of Annual General Meeting (AGM) |
| 28.11.2018 | Managing Director’s AGM Presentation |
| 28.11.2018 | Chairman’s AGM Address |
| 26.11.2018 | Final patient enrolled in landmark Alzheimer’s trial-XanADu |
| 26.11.2018 | Actinogen updated investor presentation |
| 14.11.2018 | Cleansing Notice |
| 14.11.2018 | Appendix 3B-Exercise of Options |
| 08.11.2018 | Supportive research highlights cortisol hypothesis |
| 31.10.2018 | September 2018 Quarterly Update |
| 31.10.2018 | Vesting Conditions Met |
| 30.10.2018 | Actinogen to be showcased at AusBiotech Invest 2018 |
| 29.10.2018 | Enrolment target achieved for major Alzheimer’s trial-XanADu |
| 24.10.2018 | XanADu trial to be presented at global Alzheimer conference |
| 23.10.2018 | Annual Report to Shareholders year ended 30 June 2018 |
| 23.10.2018 | Notice of Annual General Meeting/Proxy Form |
| 22.10.2018 | Recruitment to close for important Alzheimer’s trial-XanADu |
| 17.10.2018 | Actinogen to be showcased at key conferences |
| 16.10.2018 | Becoming a substantial holder from AEF |
| 10.10.2018 | R&D Tax Rebate Received Totalling $3.15 Million |
| 28.09.2018 | Notification of 2018 Annual General Meeting Date |
| 18.09.2018 | Cleansing Notice |
| 18.09.2018 | Appendix 3B-Exercise of Options |
| 11.09.2018 | Actinogen to Present to Investors in Singapore & Sydney |
| 29.08.2018 | Appendix 4G |
| 29.08.2018 | Appendix 4E & Financial Statements |
| 22.08.2018 | DSMB reaffirms recommendation to continue XanADu without change |
| 15.08.2018 | XanADu Patient Enrolment Advancing Towards Completion |
| 30.07.2018 | Updated Xanamem Clinical Development Program |
| 25.07.2018 | ACW June 2018 Quarterly Report |
| 24.07.2018 | Cleansing Notice |
| 24.07.2018 | Appendix 3B |
| 24.07.2018 | Ceasing to be a substantial holder |
| 17.07.2018 | Placement under Share Purchase Plan Shortfall |
| 16.07.2018 | Appendix 3Y-Dr Bill Ketelbey |
| 16.07.2018 | Appendix 3Y-Dr Geoff Brooke |
| 13.07.2018 | Appendix 3B-Share Purchase Plan |
| 12.07.2018 | Share Purchase Plan Completed |
| 12.07.2018 | Cleansing Notice |
| 12.07.2018 | Appendix 3B |
| 06.07.2018 | New Study Sites Added to Accelerate Patient Recruitment |
| 05.07.2018 | Cleansing Notice |
| 05.07.2018 | Appendix 3B – Exercise of Options |
| 05.07.2018 | Results of Meeting |
| 19.06.2018 | Change of Address |
| 06.06.2018 | Share Purchase Plan |
| 05.06.2018 | Notice of General Meeting/Proxy Form |
| 05.06.2018 | Appendix 3Y-Dr George Morstyn |
| 31.05.2018 | Becoming a substantial holder |
| 31.05.2018 | Actinogen Medical to present at BIO International 2018 |
| 31.05.2018 | Change in substantial holding |
| 30.05.2018 | Ceasing to be a substantial holder |
| 28.05.2018 | Information Required Under ASX Listing Rule 3.10.5A |
| 28.05.2018 | Cleansing Notice |
| 28.05.2018 | Appendix 3B |
| 28.05.2018 | Actinogen Medical Investor Conference Call |
| 23.05.2018 | Placement to Raise $15m with Cornerstone Investment by Leading USA Biotech Investor |
| 23.05.2018 | XanADu Interim Analysis-Continuation Without Change |
| 21.05.2018 | Trading Halt |
| 14.05.2018 | Cleansing Notice |
| 14.05.2018 | Appendix 3B-Exercise of Options |
| 10.05.2018 | XanADu Interim Analysis on track for May/June |
| 26.04.2018 | March 2018 Quarterly Report |
| 18.04.2018 | Cleansing Notice |
| 18.04.2018 | Appendix 3B-Exercise of Options |
| 11.04.2018 | New Analyst Report on Actinogen Medical |
| 03.04.2018 | Appendix 3B |
| 21.03.2018 | Mid-Way Point Reached in Landmark Alzheimer’s Trial – XanADu |
| 19.03.2018 | Investor Presentation |
| 07.03.2018 | Invitation to Investor Briefing |
| 15.02.2018 | Appendix 4D & Half-Year Financial Statements |
| 12.02.2018 | Strong Recruitment Progress in Alzheimer’s Trial |
| 06.02.2018 | New Data Supports Cortisol Hypothesis |
| 31.01.2018 | ACW – December 2017 Quarterly Report |
| 29.01.2018 | ACW – Change in substantial holding |
| 22.01.2018 | Appendix 3Y-Dr Geoff Brooke |
| 22.01.2018 | Cleansing Notice |
| 22.01.2018 | Appendix 3B |
| 18.01.2018 | Results of Meeting |
| 02.01.2018 | Lapse of Unlisted Options |
| 21.12.2017 | Change of Directors Interest Notice x 3 |
| 21.12.2017 | Appendix 3B |
| 18.12.2017 | Notice of General Meeting/Proxy Form |
| 14.12.2017 | Completion of Cancellation of Unvested Loan Shares |
| 13.12.2017 | Change in substantial holding |
| 08.12.2017 | Cleansing Notice |
| 08.12.2017 | Appendix 3B-Placement |
| 07.12.2017 | Letter to Ineligible Shareholders |
| 01.12.2017 | Letter to Optionholders |
| 01.12.2017 | Appendix 3B |
| 01.12.2017 | Prospectus |
| 01.12.2017 | Appendix 3X – Dr Morstyn |
| 01.12.2017 | Appendix 3B |
| 01.12.2017 | Amgen Pioneer Dr George Morstyn Joins Actinogen Board |
| 29.11.2017 | Results of Annual General & Special General Meetings |
| 29.11.2017 | Early Efficacy & Safety Data Planned for XanADu Trial |
| 29.11.2017 | Placement Fully Funds Completion of XanADu Alzheimer’s Trial |
| 29.11.2017 | Managing Director’s Annual General Meeting Presentation |
| 29.11.2017 | Chairman’s Annual General Meeting Address |
| 27.11.2017 | Trading Halt Request |
| 22.11.2017 | Leading Alzheimer’s Researchers to Address Shareholders |
| 15.11.2017 | R&D Rebate Received Totalling $1.22 Million |
| 02.11.2017 | Amgen Pioneer to Join Actinogen Board |
| 30.10.2017 | Quarterly Update & Appendix 4C |
| 23.10.2017 | Annual Report to Shareholders |
| 23.10.2017 | Notice of Special General Meeting & Proxy Form |
| 23.10.2017 | Notice of Annual General Meeting/Proxy Form |
| 17.10.2017 | Actinogen to be showcased at key conferences |
| 12.10.2017 | Investor Newsletter |
| 11.10.2017 | Final Major Market Patent Granted for Xanamem |
| 22.09.2017 | Lapse of Unlisted Options |
| 07.09.2017 | First patient completes landmark Alzheimer’s disease trial |
| 18.08.2017 | Appendix 4E & Financial Statements |
| 18.08.2017 | Appendix 4G |
| 16.08.2017 | First UK patient treated in ground-breaking Alzheimer’s clinical trial |
| 14.08.2017 | Final Director’s Interest Notice |
| 14.08.2017 | Resignation of Director |
| 26.07.2017 | June Quarterly Update |
| 19.07.2017 | Actinogen Presenting at Bioshares Biotech 2017 Summit |
| 12.07.2017 | Appendix 3B – Issue of Employee Options |
| 07.07.2017 | Appendix 3Y – Change of Director’s Interest Notice |
| 03.07.2017 | Lapse of Unlisted Options |
| 16.05.2017 | First patient treated in landmark Alzheimer’s disease clinical trial |
| 09.05.2017 | Appendix 3B – Exercise of Options |
| 09.05.2017 | Section 708A Notice |
| 26.04.2017 | Becoming a substantial holder |
| 26.04.2017 | Section 708A Notice |
| 26.04.2017 | Appendix 3B – Exercise of Options |
| 26.04.2017 | March Quarterly Update |
| 29.03.2017 | Appendix 3Y – Change of Director’s Interest Notice |
| 27.03.2017 | Latest Investor Presentation |
| 27.03.2017 | Appendix 3Y – Change of Director’s Interest Notice |
| 27.03.2017 | Appendix 3B |
| 16.03.2017 | Quarterly Investor Newsletter |
| 08.03.2017 | TGA Regulatory Approval for Alzheimer’s Phase II Trial |
| 01.03.2017 | Appendix 3X – Initial Director’s Interest Notice |
| 01.03.2017 | Actinogen Medical Appoints Dr Geoff Brooke as Chairman |
| 23.01.2017 | Appendix 4C – Quarterly |
| 09.01.2017 | Ceasing to be a substantial holder |
| 03.01.2017 | Lapse of Unlisted Options |
| 03.01.2017 | FDA Approval to Commence Alzheimer’s Disease Clinical Trial |
| 19.12.2016 | Significant Advance in Development of Alzheimer’s Drug |
| 06.12.2016 | Xanamem Research Presented at CTAD |
| 30.11.2016 | Results of Annual General Meeting |
| 30.11.2016 | Retirement of Martin Rogers as Chairman of Actinogen Medical |
| 30.11.2016 | Appendix 3Z |
| 30.11.2016 | Chairman’s AGM Address |
| 30.11.2016 | CEO’s Presentation to AGM |
| 26.10.2016 | Appendix 4C – Quarterly |
| 24.10.2016 | Annual Report to Shareholders |
| 24.10.2016 | Notice of Annual General Meeting / Proxy Form |
| 14.10.2016 | Ceasing to be a Substantial Holder |
| 06.10.2016 | Ceasing to be a Substantial Holder |
| 05.10.2016 | Changes to the Actinogen Medical Board |
| 29.09.2016 | FDA Feedback on Xanamem Alzheimer’s Trial |
| 05.09.2016 | R&D Tax Rebate |
| 01.09.2016 | Investor Update – August 2016 |
| 31.08.2016 | Appendix 4G |
| 31.08.2016 | Appendix 4E & Financial Statements |
| 24.08.2016 | Ceasing to be a Substantial Shareholder |
| 17.08.2016 | Less Than Marketable Parcel Sale |
| 28.07.2016 | Landmark Research on Excess Cortisol & Alzheimer’s Disease |
| 20.07.2016 | US Patent Granted – Further Extends Xanamem Protection |
| 15.07.2016 | US Roadshow Investor Presentation |
| 15.07.2016 | Appendix 4C Quarterly |
| 08.07.2016 | Issue of Employee Options |
| 20.05.2016 | Change of Share Register Notification |
| 06.05.2016 | Section 708A Notice |
| 06.05.2016 | Appendix 3B |
| 03.05.2016 | BioEquity & AusBiotech Asia Investor Presentation May 2016 |
| 15.04.2016 | Appendix 4C – Quarterly |
| 22.03.2016 | Launch of XanADu Phase II Clinical Trial |
| 10.03.2016 | Xanamem Cortisol Hypothesis Investor Presentation |
| 19.02.2016 | Appendix 4D & Half Year Report |
| 09.02.2016 | R&D Tax Rebate |
| 27.01.2016 | Appendix 4C – Quarterly |
| 04.01.2016 | Appendix 3Y – Dr Bill Ketelbey |
| 01.12.2015 | Investor Update – December 2015 |
| 17.11.2015 | Change of Company Name |
| 12.11.2015 | Results of AGM |
| 12.11.2015 | CEO’s AGM Presentation |
| 12.11.2015 | Chairman’s AGM Address |
| 06.11.2015 | Release of Securities from Voluntary Escrow |
| 15.10.2015 | Appendix 4C – Quarterly |
| 07.10.2015 | Understanding Alzheimer’s Symposium |
| 07.10.2015 | Annual Report to Shareholders |
| 07.10.2015 | Notice of Annual General Meeting and Proxy Form |
| 30.09.2015 | Expiry of Listed Options |
| 29.09.2015 | Positive Trial Results for Alzheimer’s Drug Xanamem |
| 28.09.2015 | Trading Halt |
| 31.08.2015 | Appendix 4G |
| 31.08.2015 | Expiry of Listed Options & Waiver of Listing Rule 6.24 |
| 31.08.2015 | Appendix 4E & Financial Statements |
| 17.08.2015 | Investor Update August 2015 |
| 12.08.2015 | Employee Share Plan Vesting Conditions Met |
| 11.08.2015 | Employee Share Plan Vesting Conditions Met |
| 11.08.2015 | Clinical Trial Successfully Completed with Xanamem |
| 16.07.2015 | Appendix 4C – Quarterly |
| 07.07.2015 | Investor Roadshow Presentation |
| 21.05.2015 | Employee Share Plan Vesting Conditions Met |
| 21.05.2015 | ASX Spotlight Series Singapore/Hong Kong May 2015 |
| 20.05.2015 | Appendix 3B |
| 20.05.2015 | Appendix 3Y: Dr Anton Uvarov |
| 20.05.2015 | Appendix 3Y: Dr Bill Ketelbey |
| 20.05.2015 | Appendix 3Y: Dr Jason Loveridge |
| 20.05.2015 | Appendix 3Y: Martin Rogers |
| 14.05.2015 | Notice of Change of Interests of Substantial Holder |
| 12.05.2015 | Successful Completion of First Stage of Alzheimer’s Drug Trial |
| 07.05.2015 | Change in Substantial Holding |
| 07.05.2015 | Ceasing to be a Substantial Holder |
| 06.05.2015 | Information Required Under Listing Rule 3.10.5A |
| 06.05.2015 | Section 708A Notice |
| 06.05.2015 | Appendix 3B |
| 01.05.2015 | Notice Under ASIC Class Order (CO 09-425) |
| 30.04.2015 | Share Purchase Plan |
| 28.04.2015 | Change in Substantial Shareholding |
| 27.04.2015 | Change in Substantial Shareholding x 2 |
| 24.04.2015 | Ethics Approval Granted for Second Stage of Phase I Study |
| 24.04.2015 | Successful Capital Raising to Support Alzheimer’s Research |
| 24.04.2015 | Appendix 4C: Quarterly |
| 22.04.2015 | Trading Halt |
| 16.04.2015 | Further Clinical Trial Update on Xanamem |
| 16.04.2015 | Xanamem Clinical Advisory Board (XCAB) Conference Call Transcript |
| 15.04.2015 | Investor Update – April 2015 |
| 13.04.2015 | EU Patent Granted – Further Extends Xanamem Protection |
| 13.04.2015 | Investor Presentation – April 2015 |
| 13.04.2015 | Xanamem Clinical Advisory Board (XCAB) Conference Call |
| 27.02.2015 | Appendix 4D & Half Year Report |
| 24.02.2015 | First Participants Recruited for Second Phase I Xanamem Study |
| 24.02.2015 | Employee Share Plan Vesting Conditions Met |
| 17.02.2015 | Investor Presentation – February 2015 |
| 16.02.2015 | Ethics Approval Granted for Second Phase I Study of Xanamem |
| 16.02.2015 | Investor Update – February 2015 |
| 29.01.2015 | Appendix 4C: Quarterly |
| 16.01.2015 | Employee Share Plan Vesting Conditions Met |
| 09.01.2015 | US Investor Presentation – January 2015 |
| 07.01.2015 | Response to ASX Query – Price Query |
| 18.12.2014 | ACW Board Changes |
| 18.12.2014 | Appendix 3Z – Final Director’s Interest Notice |
| 18.12.2014 | Appendix 3X – Dr Bill Ketelbey |
| 15.12.2014 | Section 708A Notice |
| 15.12.2014 | Appendix 3B |
| 15.12.2014 | ACW Appoints Dr Bill Ketelbey as CEO |
